Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus

Journal of Medical Virology

Volumn 60, Issue 3, 2000, Pages 264-268

  Lee, Jung Hun ^a   Teuber, Gerlinde ^a   Von Wagner, Michael ^a   Roth, Willi Kurt ^b   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Blutspendedienst Hessen ^*  (Germany)

Author keywords

Hepatitis C virus; Hypervariable region; Interleukin 12; Quasispecies; Single strand conformation polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 12; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HEPATITIS C; HUMAN; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-12; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 0033977738     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200003)60:3<264::AID-JMV3>3.0.CO;2-J     Document Type: Article

References (18)

1. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. 1998. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27:223-227.
2. Cabot B, Esteban JI, Martell M, Genesca J, Vargas V, Esteban R, Guardia J, Gomez J. 1997. Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions. J Virol 71:1732-1734.
3. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad USA 91:7792-7796.
4. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann Rev Immunol 16:495-521.
5. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kolsch E, Podlaski FJ, Gately MK, Rude E. 1995. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25:823-829.
6. Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD. 1993. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 67:7522-7532.
7. Kumar U, Brown J, Monjardino J, Thomas HC. 1993. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis 167:726-730.
8. Kurosaki M, Enomoto N, Marumo F, Sato C. 1994. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology 205:161-169.
9. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR [published erratum appears in Nature 1989 Jun 8;339(6224):490]. Nature 339:237-238.
10. Lee JH, Roth WK, Zeuzem S. 1997a. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J Hepatol 26:1001-1009.
11. Lee JH, Stripf T, Roth WK, Zeuzem S. 1997b. Non-isotopic detection of hepatitis C virus quasispecies by single strand conformation polymorphism. J Med Virol 53:245-251.
12. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225-3229.
13. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, Chisari FV. 1996. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70:7092-7102.
14. Sakuma I, Enomoto N, Kurosaki M, Marumo F, Sato C. 1996. Selection of hepatitis C virus quasispecies during interferon treatment. Arch Virol 141:1921-1932.
15. Trinchieri G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 13:251-76.
16. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad USA 89:3468-3472.
17. Yun ZB, Odeberg J, Lundeberg J, Weiland O, Uhlen M, Sonnerborg A. 1996. Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load. J Infect Dis 173:992-996.
18. Zeuzem S, Hopf U, Carreno V, Diago M, Shiffman M, Grüne S, Dudley FJ, Rakhit A, Rittweger K, Yap SH, KoffRS, Thomas HC. 1999. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 29:1280-1287.